Why the study?
Pharmacological treatment of HFREF has evolved with discoveries of new pathophysiological systems and therapeutic targets to reduce high morbidity and mortality.
Answers are grounded in this paper and cite their sources.
This review highlights the essential pharmacological pillars for the treatment of heart failure with reduced ejection fraction to reduce morbidity and mortality.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bonatto et al. (2022) conducted a review in Heart failure with reduced ejection fraction (HFREF). Combination therapy (NARI, beta blockers, MRA, and SGLT2 inhibitors) vs. ACEI or ARB in conjunction with a beta blocker was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: